Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (8025)	5/12/1998 6:49:00 PM
From: Frostman	Respond to of 23519

This from WSJ Interactive:Total Viagra Prescriptions Up To 286,271 For Wk Ended 5/1, source.. Dow Jones Newswires, this article focused on the increase in Viagra scripts and mentions VVUS as follows... <<..... While prescriptions for Vivus' Muse continue to fall, don't count it out entirely, some market observers said. PaineWebber Inc. analyst Charlie Olsziewski said Muse should benefit from the dramatically increased number of impotent men who are for the first time seeking treatment for their condition thanks to Viagra. The Muse system, which injects a drug through the urethra to treat impotence, should be able to capture some of the patients who get no benefit from Viagra, Olsziewski said. He expects a similar benefit for Pharmacia's Caverject system, noting however that therapy may turn off many men because it requires a needle injection into the penis. New prescriptions for the Muse continue to fall sharply but renewals have been more steady, Olsziewski said. If new prescriptions do eventually return, he believes they could start doing so in the next two to four weeks. Olsziewski said he is bullish on Vivus' long-term prospects but added that he will keep his neutral rating on the stock "until they can demonstrate they can handle the fallout" from Viagra. PaineWebber was an underwriter of Vivus' follow-on offering in June 1996 of 2 million common shares.>> A U.S. perspective only, but Fair enough, Frostman